$CNTA
Centessa Pharmaceuticals plc Stock $cnta

$cnta Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000184790323000063 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.05M	$13.77M	$55.20M
YoY Change	11.58%	6.01%	28.71%
% of Gross Profit
Research & Development	$32.83M	$27.84M	$155.1M
YoY Change	-10.93%	-32.98%	62.12%
% of Gross Profit
Depreciation & Amortization	$89.00K	$36.00K	$131.0K
YoY Change	217.86%	200.0%	285.29%
% of Gross Profit
Operating Expenses	$32.83M	$41.60M	$155.1M
YoY Change	-10.93%	-28.63%	0.95%
Operating Profit	-$48.88M		-$212.3M
YoY Change	-8.16%
Interest Expense	$2.345M	-$2.164M	-$7.033M
YoY Change	-267.98%	70.13%	500.09%
% of Operating Profit
Other Income/Expense, Net	-$1.346M	-$70.00K	$2.342M
YoY Change	-786.73%	-93.61%	-141.08%
Pretax Income	-$50.04M	-$43.84M	-$217.0M
YoY Change	-8.05%	-27.73%	-43.05%
Income Tax	$677.0K	-$664.0K	-$747.0K
% Of Pretax Income
Net Earnings	-$50.71M	-$43.17M	-$216.2M
YoY Change	-6.94%	-28.96%	-43.26%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.53		-$2.31
Diluted Earnings Per Share	-$0.53	-$0.46	-$2.31
COMMON SHARES
Basic Shares Outstanding	94.96M shares	94.60M shares	93.40M shares
Diluted Shares Outstanding	94.94M shares		93.40M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$346.2M	$393.6M	$393.6M
YoY Change	-36.41%	-33.85%	-33.85%
Cash & Equivalents	$260.0M	$393.6M
Short-Term Investments	$86.24M
Other Short-Term Assets	$3.127M	$3.271M	$17.38M
YoY Change	179.2%	229.41%	2.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$384.3M	$437.7M	$437.7M
YoY Change	-33.87%	-30.38%	-30.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.219M	$1.168M	$1.168M
YoY Change	225.94%	620.99%	620.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.040M	$5.392M	$5.392M
YoY Change	875.77%	671.39%	671.39%
Total Long-Term Assets	$19.53M	$6.560M	$6.560M
YoY Change	1866.77%	661.9%	661.9%
TOTAL ASSETS
Total Short-Term Assets	$384.3M	$437.7M	$437.7M
Total Long-Term Assets	$19.53M	$6.560M	$6.560M
Total Assets	$403.9M	$444.3M	$444.3M
YoY Change	-30.63%	-29.43%	-29.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.37M	$13.84M	$13.84M
YoY Change	114.8%	71.56%	71.56%
Accrued Expenses	$15.32M	$24.50M	$22.92M
YoY Change	-25.3%	47.84%	45.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$29.69M	$38.34M	$38.34M
YoY Change	9.16%	55.61%	55.61%
LONG-TERM LIABILITIES
Long-Term Debt	$71.60M	$69.80M	$69.80M
YoY Change	-4.28%	-7.79%	-7.79%
Other Long-Term Liabilities	$9.313M	$0.00	$0.00
YoY Change	21558.14%	-100.0%	-100.0%
Total Long-Term Liabilities	$71.60M	$69.80M	$69.80M
YoY Change	-4.33%	-7.85%	-38.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.69M	$38.34M	$38.34M
Total Long-Term Liabilities	$71.60M	$69.80M	$69.80M
Total Liabilities	$110.6M	$108.1M	$108.1M
YoY Change	8.39%	-21.69%	-21.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$652.6M	-$601.9M
YoY Change	48.25%	56.07%
Common Stock	$266.0K	$265.0K
YoY Change	1.53%	5.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$293.3M	$336.2M	$336.2M
YoY Change
Total Liabilities & Shareholders Equity	$403.9M	$444.3M	$444.3M
YoY Change	-30.63%	-29.43%	-29.43%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$50.71M	-$43.17M	-$216.2M
YoY Change	-6.94%	-28.96%	-43.26%
Depreciation, Depletion And Amortization	$89.00K	$36.00K	$131.0K
YoY Change	217.86%	200.0%	285.29%
Cash From Operating Activities	-$47.84M	-$51.56M	-$200.5M
YoY Change	-4.36%	-8.62%	48.43%
INVESTING ACTIVITIES
Capital Expenditures	$88.00K	$652.0K	$1.137M
YoY Change	-63.33%	-1118.75%	-711.29%
Acquisitions
YoY Change
Other Investing Activities	-$86.25M	$206.0K	-$206.0K
YoY Change			-100.32%
Cash From Investing Activities	-$86.34M	-$446.0K	-$931.0K
YoY Change	35873.33%	596.87%	-101.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	89.00K	$457.0K
YoY Change	-100.0%	-99.88%	-99.93%
NET CHANGE
Cash From Operating Activities	-$47.84M	-51.56M	-$200.5M
Cash From Investing Activities	-$86.34M	-446.0K	-$931.0K
Cash From Financing Activities	$0.00	89.00K	$457.0K
Net Change In Cash	-$133.7M	-51.92M	-$201.4M
YoY Change	164.05%	-389.45%	-134.24%
FREE CASH FLOW
Cash From Operating Activities	-$47.84M	-$51.56M	-$200.5M
Capital Expenditures	$88.00K	$652.0K	$1.137M
Free Cash Flow	-$47.93M	-$52.22M	-$201.7M
YoY Change	-4.64%	-7.36%	49.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Extension Extension	9999
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022Q4	cnta	Tax Incentive Receivable Current TaxIncentiveReceivableCurrent	24166000	usd
CY2021Q4	cnta	Tax Incentive Receivable Current TaxIncentiveReceivableCurrent	15392000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19937000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18300000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	437747000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	628774000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1168000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	162000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5392000	usd
CY2022Q4	us-gaap	Assets Assets	444307000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13836000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24502000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38338000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	69800000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	0	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	37700000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	152500000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89988228	shares
CY2022	cnta	Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue	1980000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	220454000	usd
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	37000	usd
CY2022	cnta	Debt Issuance Expense DebtIssuanceExpense	0	usd
	cnta	Debt Issuance Expense DebtIssuanceExpense	1331000	usd
CY2021Q1	cnta	Debt Issuance Expense DebtIssuanceExpense	0	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2185000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-218392000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-380293000	usd
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-722000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.31
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.07
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93400513	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93400513	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75166456	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75166456	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	491554000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37748000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	799000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24965000	usd
CY2022	cnta	Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Aggregate Intrinsic Value Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsAggregateIntrinsicValueVested	0	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	505000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2185000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-216207000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	336169000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-4651000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6250000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	262686000	usd
	cnta	Adjustments To Additional Paid In Capital Forgiveness Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalForgivenessOfConvertibleDebt	6199000	usd
	cnta	Stock Issued During Period Value Conversion Of Convertible Preferred Stock StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock	0	usd
	cnta	Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Aggregate Intrinsic Value Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsAggregateIntrinsicValueVested	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-381071000	usd
CY2020Q4	us-gaap	Members Equity MembersEquity	-22423000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-829000	usd
CY2021Q1	us-gaap	Members Equity MembersEquity	-23145000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-216207000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-829000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	220454000	usd
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	24965000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	14851000	usd
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	131000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	34000	usd
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	usd
CY2022	cnta	Financial Instruments Change In Fair Value Gain Loss Net FinancialInstrumentsChangeInFairValueGainLossNet	3920000	usd
	cnta	Financial Instruments Change In Fair Value Gain Loss Net FinancialInstrumentsChangeInFairValueGainLossNet	-15782000	usd
CY2021Q1	cnta	Financial Instruments Change In Fair Value Gain Loss Net FinancialInstrumentsChangeInFairValueGainLossNet	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2857000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	11711000	usd
	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	6796000	usd
CY2021Q1	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	-74000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3732000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16164000	usd
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-681000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6351000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4157000	usd
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-358000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6261000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	12968000	usd
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-589000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	173000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	676000	usd
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-28000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-200546000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-135109000	usd
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1049000	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	63442000	usd
CY2021Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1137000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	186000	usd
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-206000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2021Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-931000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	63256000	usd
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	241597000	usd
CY2021Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	344136000	usd
CY2021Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	73930000	usd
CY2021Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	718000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	779000	usd
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-261000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-295000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	457000	usd
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	590116000	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-969000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7227000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	393644000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	595082000	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6258000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	7277000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1483000	usd
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	1299000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	cnta	Stock Issued To Settle Contingent Value Rights StockIssuedToSettleContingentValueRights	39680000	usd
	cnta	Stock Issued To Settle Contingent Value Rights StockIssuedToSettleContingentValueRights	0	usd
CY2021Q1	cnta	Stock Issued To Settle Contingent Value Rights StockIssuedToSettleContingentValueRights	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Stock Issued1 StockIssued1	262698000	usd
CY2021Q1	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	cnta	Contingent Value Rights Issued ContingentValueRightsIssued	0	usd
	cnta	Contingent Value Rights Issued ContingentValueRightsIssued	22618000	usd
CY2021Q1	cnta	Contingent Value Rights Issued ContingentValueRightsIssued	0	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	6250000	usd
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
CY2022	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	usd
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	6199000	usd
CY2021Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	usd
CY2021Q2	cnta	Sale Of Stock Number Of Ordinary Shares Per American Depositary Shares SaleOfStockNumberOfOrdinarySharesPerAmericanDepositaryShares	1	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.002
CY2021Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	344100000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-601900000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393600000	usd
CY2022	cnta	Cash And Cash Equivalents At Carrying Value Sufficient Funding Term CashAndCashEquivalentsAtCarryingValueSufficientFundingTerm	P12M
CY2022	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	11	subsidiary
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on previously reported net loss or comprehensive loss.</span></div>
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2800000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3600000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated and combined financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated and combined financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include accrued research and development expenses, the note purchase agreement, share-based compensation, contingent value rights, and, prior to the IPO, the fair value of the Company’s ordinary shares.</span></div>
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	131000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	34000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18300000	usd
CY2022Q4	cnta	Cumulative Payments Under Note Purchase Agreement Including Interest CumulativePaymentsUnderNotePurchaseAgreementIncludingInterest	8800000	usd
CY2022Q1	cnta	Note Purchase Agreement Percent Of Aggregate Outstanding Principal Amount Cash Balance Required NotePurchaseAgreementPercentOfAggregateOutstandingPrincipalAmountCashBalanceRequired	0.75
CY2022Q1	cnta	Note Purchase Agreement Deductible Amount Due To Company NotePurchaseAgreementDeductibleAmountDueToCompany	100000000	usd
CY2021Q4	cnta	Note Purchase Agreement Milestone Payment Percent Of Aggregate Principal Amount Issued NotePurchaseAgreementMilestonePaymentPercentOfAggregatePrincipalAmountIssued	0.30
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	12600000	usd
	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	13800000	usd
CY2022Q4	cnta	Research And Development Tax Credit Limitation Expenditure On Employees Multiple ResearchAndDevelopmentTaxCreditLimitationExpenditureOnEmployeesMultiple	3
CY2022	cnta	Research And Development Tax Credit Limitation Expenditure On Employees Additional Value ResearchAndDevelopmentTaxCreditLimitationExpenditureOnEmployeesAdditionalValue	20000	eur
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2022Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	18922	sqft
CY2022Q1	cnta	Lessee Operating Lease Number Of Options To Extend LesseeOperatingLeaseNumberOfOptionsToExtend	1	extension_term
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	75700000	usd
CY2022Q1	cnta	Note Purchase Agreement Value NotePurchaseAgreementValue	300000000	usd
CY2022Q1	cnta	Note Purchase Agreement Amount Available For Funding At The Option Of The Company And The Counterparty NotePurchaseAgreementAmountAvailableForFundingAtTheOptionOfTheCompanyAndTheCounterparty	100000000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2022	cnta	Defined Contribution Plan Minimum Contribution Percent DefinedContributionPlanMinimumContributionPercent	0.08
CY2022	cnta	Defined Contribution Plan Minimum Employer Contribution Percent DefinedContributionPlanMinimumEmployerContributionPercent	0.04
CY2022	cnta	Defined Contribution Plan Minimum Employee Contribution Percent DefinedContributionPlanMinimumEmployeeContributionPercent	0.04
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17093177	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12713326	shares
CY2022Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P6Y
CY2022Q1	cnta	Debt Instrument Reference Rate DebtInstrumentReferenceRate	0.0775
CY2022Q1	cnta	Debt Instrument Interest Rate Floor DebtInstrumentInterestRateFloor	0.0800
CY2022	us-gaap	Long Term Debt Weighted Average Interest Rate Over Time LongTermDebtWeightedAverageInterestRateOverTime	0.096
CY2022	cnta	Milestone Payment Percent Of Aggregate Principal Amount Issued Under The Notes MilestonePaymentPercentOfAggregatePrincipalAmountIssuedUnderTheNotes	0.30
CY2022	cnta	Milestone Payment Period MilestonePaymentPeriod	P5Y
CY2022Q4	cnta	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	11321000	usd
CY2021Q4	cnta	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	11224000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2788000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	4661000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	2557000	usd
CY2021Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	1422000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3271000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	993000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19937000	usd
CY2022Q4	cnta	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	10795000	usd
CY2021Q4	cnta	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	9323000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7264000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4865000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4171000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1514000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1582000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	769000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	690000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	102000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24502000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16573000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1332000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	196000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	164000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1168000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	162000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1382000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	778000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	803000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2185000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	778000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	69800000	usd
CY2022Q1	cnta	Note Purchase Agreement Deductible Amount Due To Company NotePurchaseAgreementDeductibleAmountDueToCompany	100000000	usd
CY2022Q4	us-gaap	Deposits Deposits	25000000	usd
CY2022Q1	cnta	Note Purchase Agreement Percent Of Aggregate Outstanding Principal Amount Cash Balance Required NotePurchaseAgreementPercentOfAggregateOutstandingPrincipalAmountCashBalanceRequired	0.75
CY2022Q4	cnta	Note Purchase Agreement Percent Of Aggregate Outstanding Principal Amount Cash Balance Required NotePurchaseAgreementPercentOfAggregateOutstandingPrincipalAmountCashBalanceRequired	0.90
CY2022Q4	cnta	Note Purchase Agreement Deductible Amount Due To Company NotePurchaseAgreementDeductibleAmountDueToCompany	100000000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	42800000	usd
CY2022Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	36000000	usd
CY2022Q4	cnta	Purchase Obligation To Be Paid Year One Through Four PurchaseObligationToBePaidYearOneThroughFour	6800000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2022Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	700000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	20026816	shares
CY2022	cnta	Share Based Compensation Arrangement By Share Based Payment Award Percent Of Additional Shares Authorized Each Year ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfAdditionalSharesAuthorizedEachYear	0.05
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	6010683	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24965000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14852000	usd
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11730382	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.07
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5553985	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.02
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	205107	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.89
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2390264	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.44
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14688996	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.88
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5002044	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.79
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	14688996	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.88
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.38
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	46700000	usd
CY2022Q4	us-gaap	Share Price SharePrice	3.10
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	534000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	188000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-392000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-160000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-747000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	73097000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32983000	usd
CY2022Q4	cnta	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	15624000	usd
CY2021Q4	cnta	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	8734000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7174000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6967000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1467000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1016000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	97362000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	49700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	93850000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49045000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3512000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	655000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	44800000	usd
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30500000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-173476000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-331423000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-43478000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-49534000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-216954000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-380957000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1575000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	581000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2464000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-495000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	114000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.19
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.19
CY2022	cnta	Effective Income Tax Rate Reconciliation Nondeductible Expense Write Off Of In Process Rd EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWriteOffOfInProcessRD	0
	cnta	Effective Income Tax Rate Reconciliation Nondeductible Expense Write Off Of In Process Rd EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWriteOffOfInProcessRD	-0.11
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.03
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.02
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.07
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.03
CY2022	cnta	Effective Income Tax Rate Reconciliation Losses Surrendered For Tax Incentive Percent EffectiveIncomeTaxRateReconciliationLossesSurrenderedForTaxIncentivePercent	-0.07
	cnta	Effective Income Tax Rate Reconciliation Losses Surrendered For Tax Incentive Percent EffectiveIncomeTaxRateReconciliationLossesSurrenderedForTaxIncentivePercent	-0.05
CY2022	cnta	Effective Income Tax Rate Reconciliation Non Taxable Research And Development Percent EffectiveIncomeTaxRateReconciliationNonTaxableResearchAndDevelopmentPercent	0.01
	cnta	Effective Income Tax Rate Reconciliation Non Taxable Research And Development Percent EffectiveIncomeTaxRateReconciliationNonTaxableResearchAndDevelopmentPercent	0.02
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.01
	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.02
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.03
	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.23
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.08
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, MA
CY2022	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
cnta-20221231_lab.xml	Edgar Link	unprocessable
0001847903-23-000063-index-headers.html	Edgar Link	pending
0001847903-23-000063-index.html	Edgar Link	pending
0001847903-23-000063.txt	Edgar Link	pending
0001847903-23-000063-xbrl.zip	Edgar Link	pending
a20221231ex231kpmgconsent.htm	Edgar Link	pending
a20221231ex43descriptionof.htm	Edgar Link	pending
a20221231exhibit311.htm	Edgar Link	pending
a20221231exhibit312.htm	Edgar Link	pending
a20221231exhibit321.htm	Edgar Link	pending
a20221231exhibit322.htm	Edgar Link	pending
cnta-20221231.htm	Edgar Link	pending
cnta-20221231.xsd	Edgar Link	pending
cnta-20221231_g1.jpg	Edgar Link	pending
cnta-20221231_g10.jpg	Edgar Link	pending
cnta-20221231_g11.jpg	Edgar Link	pending
cnta-20221231_g12.jpg	Edgar Link	pending
cnta-20221231_g2.jpg	Edgar Link	pending
cnta-20221231_g3.jpg	Edgar Link	pending
cnta-20221231_g4.jpg	Edgar Link	pending
cnta-20221231_g5.jpg	Edgar Link	pending
cnta-20221231_g6.jpg	Edgar Link	pending
cnta-20221231_g7.jpg	Edgar Link	pending
cnta-20221231_g8.jpg	Edgar Link	pending
cnta-20221231_g9.jpg	Edgar Link	pending
ex1021oberland2ndamendment.htm	Edgar Link	pending
ex1023drchaoemploymentagre.htm	Edgar Link	pending
ex211subsidiariesofregistr.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
cnta-20221231_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cnta-20221231_cal.xml	Edgar Link	unprocessable
cnta-20221231_def.xml	Edgar Link	unprocessable
cnta-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNTA
Centessa Pharmaceuticals plc Stock $cnta

2023 Q1 Form 10-K Financial Statement

#000184790323000063 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTA Centessa Pharmaceuticals plc Stock $cnta

2023 Q1 Form 10-K Financial Statement

#000184790323000063 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTA
Centessa Pharmaceuticals plc Stock $cnta